ES2714406T3 - Composiciones que comprenden fosfatasa alcalina y / o péptido natriurético y procedimientos de uso de las mismas - Google Patents

Info

Publication number

ES2714406T3

ES2714406T3 ES12842640T ES12842640T ES2714406T3 ES 2714406 T3 ES2714406 T3 ES 2714406T3 ES 12842640 T ES12842640 T ES 12842640T ES 12842640 T ES12842640 T ES 12842640T ES 2714406 T3 ES2714406 T3 ES 2714406T3

Authority

ES

Spain

Prior art keywords

amino acid

seq

sequence

acid sequence

polypeptide

Prior art date

2011-10-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 58
• 102000002260 Alkaline Phosphatase Human genes 0.000 title claims abstract description 54
• 108020004774 Alkaline Phosphatase Proteins 0.000 title claims abstract description 54
• 108020001621 Natriuretic Peptide Proteins 0.000 title claims description 181
• 102000004571 Natriuretic peptide Human genes 0.000 title claims description 181
• 239000000692 natriuretic peptide Substances 0.000 title claims description 147
• 239000000203 mixture Substances 0.000 title claims description 63
• 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 396
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 353
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 332
• 229920001184 polypeptide Polymers 0.000 claims abstract description 327
• 150000001413 amino acids Chemical class 0.000 claims abstract description 195
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 74
• 208000009905 Neurofibromatoses Diseases 0.000 claims abstract description 42
• 201000004931 neurofibromatosis Diseases 0.000 claims abstract description 42
• 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 17
• 125000000539 amino acid group Chemical group 0.000 claims description 375
• 229940024606 amino acid Drugs 0.000 claims description 238
• 235000001014 amino acid Nutrition 0.000 claims description 238
• 210000000988 bone and bone Anatomy 0.000 claims description 121
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 78
• 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 claims description 73
• 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 claims description 73
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 55
• 210000004899 c-terminal region Anatomy 0.000 claims description 48
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 37
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 37
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 30
• 208000022145 neurocutaneous syndrome Diseases 0.000 claims description 28
• 239000012634 fragment Substances 0.000 claims description 26
• 238000003776 cleavage reaction Methods 0.000 claims description 24
• 230000007017 scission Effects 0.000 claims description 24
• 235000003704 aspartic acid Nutrition 0.000 claims description 19
• 102000005600 Cathepsins Human genes 0.000 claims description 18
• 108010084457 Cathepsins Proteins 0.000 claims description 18
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 18
• 229910052720 vanadium Inorganic materials 0.000 claims description 17
• 108060003951 Immunoglobulin Proteins 0.000 claims description 16
• 102000018358 immunoglobulin Human genes 0.000 claims description 16
• 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 15
• 235000013922 glutamic acid Nutrition 0.000 claims description 15
• 239000004220 glutamic acid Substances 0.000 claims description 15
• 101000928278 Homo sapiens Natriuretic peptides B Proteins 0.000 claims description 14
• 102100036836 Natriuretic peptides B Human genes 0.000 claims description 14
• 239000000018 receptor agonist Substances 0.000 claims description 14
• 229940044601 receptor agonist Drugs 0.000 claims description 14
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 13
• KJBQDYDTQCIAFO-ZLELNMGESA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(C)C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O KJBQDYDTQCIAFO-ZLELNMGESA-N 0.000 claims description 12
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 12
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 12
• 239000004471 Glycine Substances 0.000 claims description 11
• SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 9
• 235000011180 diphosphates Nutrition 0.000 claims description 9
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 8
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 8
• 210000001519 tissue Anatomy 0.000 claims description 8
• SEFLNGWGXSFZMH-DQZFIDPSSA-N (2s)-2-aminobutanedioic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC(O)=O SEFLNGWGXSFZMH-DQZFIDPSSA-N 0.000 claims description 7
• 230000000968 intestinal effect Effects 0.000 claims description 5
• 230000003169 placental effect Effects 0.000 claims description 2
• 150000001510 aspartic acids Chemical class 0.000 claims 1
• FJEKYHHLGZLYAT-FKUIBCNASA-N galp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C1=CNC=N1 FJEKYHHLGZLYAT-FKUIBCNASA-N 0.000 claims 1
• 210000004602 germ cell Anatomy 0.000 claims 1
• 150000002307 glutamic acids Chemical class 0.000 claims 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 289
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 115
• 101800002899 Soluble alkaline phosphatase Proteins 0.000 description 100
• 125000005647 linker group Chemical group 0.000 description 96
• 208000035475 disorder Diseases 0.000 description 66
• 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 65
• 101800000060 C-type natriuretic peptide Proteins 0.000 description 65
• 230000035772 mutation Effects 0.000 description 60
• 150000007523 nucleic acids Chemical class 0.000 description 59
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 57
• 201000010099 disease Diseases 0.000 description 49
• 230000004927 fusion Effects 0.000 description 49
• 108020004707 nucleic acids Proteins 0.000 description 49
• 102000039446 nucleic acids Human genes 0.000 description 49
• 241000282414 Homo sapiens Species 0.000 description 46
• 241000699670 Mus sp. Species 0.000 description 44
• 206010008723 Chondrodystrophy Diseases 0.000 description 37
• -1 for example Chemical compound 0.000 description 37
• 108010038664 atrial natriuretic factor receptor B Proteins 0.000 description 35
• 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 description 34
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 34
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 34
• 208000008919 achondroplasia Diseases 0.000 description 33
• 210000004027 cell Anatomy 0.000 description 33
• 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 32
• 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 32
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 28
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 28
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 28
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 28
• 206010058314 Dysplasia Diseases 0.000 description 27
• 206010049933 Hypophosphatasia Diseases 0.000 description 27
• 230000000694 effects Effects 0.000 description 27
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 26
• 208000020084 Bone disease Diseases 0.000 description 25
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 25
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 24
• 230000033558 biomineral tissue development Effects 0.000 description 24
• 208000015100 cartilage disease Diseases 0.000 description 24
• 108090000623 proteins and genes Proteins 0.000 description 24
• 238000011282 treatment Methods 0.000 description 24
• 208000011580 syndromic disease Diseases 0.000 description 23
• 239000013598 vector Substances 0.000 description 22
• 108091035707 Consensus sequence Proteins 0.000 description 21
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 21
• 230000001717 pathogenic effect Effects 0.000 description 21
• 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 21
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 20
• 230000005856 abnormality Effects 0.000 description 20
• 206010072610 Skeletal dysplasia Diseases 0.000 description 19
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 19
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 19
• 108020001507 fusion proteins Proteins 0.000 description 19
• 102000037865 fusion proteins Human genes 0.000 description 19
• 210000002464 muscle smooth vascular Anatomy 0.000 description 19
• 230000001225 therapeutic effect Effects 0.000 description 19
• 235000004400 serine Nutrition 0.000 description 18
• 230000006870 function Effects 0.000 description 17
• 238000001727 in vivo Methods 0.000 description 17
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 17
• 102000004190 Enzymes Human genes 0.000 description 16
• 108090000790 Enzymes Proteins 0.000 description 16
• 208000029578 Muscle disease Diseases 0.000 description 16
• 208000021642 Muscular disease Diseases 0.000 description 16
• 241001415513 Salpida Species 0.000 description 16
• 235000018102 proteins Nutrition 0.000 description 16
• 102000004169 proteins and genes Human genes 0.000 description 16
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 15
• 239000012528 membrane Substances 0.000 description 15
• 239000011780 sodium chloride Substances 0.000 description 15
• 238000006467 substitution reaction Methods 0.000 description 15
• 101001050607 Homo sapiens KH domain-containing, RNA-binding, signal transduction-associated protein 3 Proteins 0.000 description 14
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 14
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 14
• 102100023428 KH domain-containing, RNA-binding, signal transduction-associated protein 3 Human genes 0.000 description 14
• 206010029748 Noonan syndrome Diseases 0.000 description 14
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 14
• 235000012237 sodium aluminium phosphate Nutrition 0.000 description 14
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 13
• 206010028980 Neoplasm Diseases 0.000 description 13
• 239000002253 acid Substances 0.000 description 13
• 239000003795 chemical substances by application Substances 0.000 description 13
• 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 12
• 206010061762 Chondropathy Diseases 0.000 description 12
• 108091028043 Nucleic acid sequence Proteins 0.000 description 12
• 230000002411 adverse Effects 0.000 description 12
• 229910052799 carbon Inorganic materials 0.000 description 12
• 238000009472 formulation Methods 0.000 description 12
• 230000014509 gene expression Effects 0.000 description 12
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 12
• 101001128963 Homo sapiens Protein Dr1 Proteins 0.000 description 11
• 102100031227 Protein Dr1 Human genes 0.000 description 11
• 108010038640 atrial natriuretic factor receptor A Proteins 0.000 description 11
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 239000001509 sodium citrate Substances 0.000 description 11
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 11
• 229940038773 trisodium citrate Drugs 0.000 description 11
• 239000003981 vehicle Substances 0.000 description 11
• 208000009283 Craniosynostoses Diseases 0.000 description 10
• 206010049889 Craniosynostosis Diseases 0.000 description 10
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
• 208000020221 Short stature Diseases 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 239000013078 crystal Substances 0.000 description 10
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 10
• 108010044467 Isoenzymes Proteins 0.000 description 9
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 9
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 9
• 102000003729 Neprilysin Human genes 0.000 description 9
• 108090000028 Neprilysin Proteins 0.000 description 9
• 102000007530 Neurofibromin 1 Human genes 0.000 description 9
• 108010085793 Neurofibromin 1 Proteins 0.000 description 9
• 238000007792 addition Methods 0.000 description 9
• 235000004279 alanine Nutrition 0.000 description 9
• 238000013270 controlled release Methods 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 230000009984 peri-natal effect Effects 0.000 description 9
• COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
• 229910052698 phosphorus Inorganic materials 0.000 description 9
• 238000002560 therapeutic procedure Methods 0.000 description 9
• 230000003612 virological effect Effects 0.000 description 9
• 229910052727 yttrium Inorganic materials 0.000 description 9
• 102000043136 MAP kinase family Human genes 0.000 description 8
• 108091054455 MAP kinase family Proteins 0.000 description 8
• 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 8
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 8
• 210000000845 cartilage Anatomy 0.000 description 8
• 230000015556 catabolic process Effects 0.000 description 8
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
• 235000018417 cysteine Nutrition 0.000 description 8
• 238000006731 degradation reaction Methods 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 239000000539 dimer Substances 0.000 description 8
• WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 8
• 238000009396 hybridization Methods 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 238000002887 multiple sequence alignment Methods 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 208000007442 rickets Diseases 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• 210000002700 urine Anatomy 0.000 description 8
• 238000005406 washing Methods 0.000 description 8
• 102000004171 Cathepsin K Human genes 0.000 description 7
• 108090000625 Cathepsin K Proteins 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 7
• 206010013883 Dwarfism Diseases 0.000 description 7
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
• 239000002775 capsule Substances 0.000 description 7
• 210000001612 chondrocyte Anatomy 0.000 description 7
• 230000008021 deposition Effects 0.000 description 7
• 231100000673 dose–response relationship Toxicity 0.000 description 7
• 229910052739 hydrogen Inorganic materials 0.000 description 7
• 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 7
• 201000010828 metaphyseal dysplasia Diseases 0.000 description 7
• 230000001575 pathological effect Effects 0.000 description 7
• 150000003839 salts Chemical class 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 210000002303 tibia Anatomy 0.000 description 7
• 239000004474 valine Substances 0.000 description 7
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 6
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
• 241000283690 Bos taurus Species 0.000 description 6
• 206010010904 Convulsion Diseases 0.000 description 6
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 6
• 101100180983 Mus musculus Khdrbs3 gene Proteins 0.000 description 6
• 206010031243 Osteogenesis imperfecta Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
• 239000004473 Threonine Substances 0.000 description 6
• 230000004913 activation Effects 0.000 description 6
• 230000018678 bone mineralization Effects 0.000 description 6
• 230000007812 deficiency Effects 0.000 description 6
• 210000003414 extremity Anatomy 0.000 description 6
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
• 231100000518 lethal Toxicity 0.000 description 6
• 230000001665 lethal effect Effects 0.000 description 6
• 125000003729 nucleotide group Chemical group 0.000 description 6
• 210000000963 osteoblast Anatomy 0.000 description 6
• 210000000614 rib Anatomy 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 210000000689 upper leg Anatomy 0.000 description 6
• WMSPZRZYIGOEDS-QMMMGPOBSA-N 4-[[(1s)-5-amino-1-carboxypentyl]amino]-3,5-dinitrobenzoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC1=C([N+]([O-])=O)C=C(C(O)=O)C=C1[N+]([O-])=O WMSPZRZYIGOEDS-QMMMGPOBSA-N 0.000 description 5
• 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 5
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 5
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 5
• 206010024503 Limb reduction defect Diseases 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 208000006938 Schwannomatosis Diseases 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 230000036772 blood pressure Effects 0.000 description 5
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 5
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
• 230000007547 defect Effects 0.000 description 5
• 201000010072 hypochondroplasia Diseases 0.000 description 5
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
• 229960000310 isoleucine Drugs 0.000 description 5
• 208000032839 leukemia Diseases 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 239000000178 monomer Substances 0.000 description 5
• 201000009494 neurilemmomatosis Diseases 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 208000003580 polydactyly Diseases 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 230000002028 premature Effects 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 102000016914 ras Proteins Human genes 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 238000004904 shortening Methods 0.000 description 5
• 210000003625 skull Anatomy 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• 201000010028 Acrocephalosyndactylia Diseases 0.000 description 4
• 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 4
• 206010002961 Aplasia Diseases 0.000 description 4
• 206010006002 Bone pain Diseases 0.000 description 4
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 4
• 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 4
• 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 4
• 208000032170 Congenital Abnormalities Diseases 0.000 description 4
• 206010010356 Congenital anomaly Diseases 0.000 description 4
• 108010016626 Dipeptides Proteins 0.000 description 4
• 241000282326 Felis catus Species 0.000 description 4
• DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
• 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 description 4
• 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 4
• 208000001182 Kniest dysplasia Diseases 0.000 description 4
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
• 239000004472 Lysine Substances 0.000 description 4
• 208000011262 Micromelia Diseases 0.000 description 4
• 101100084030 Mus musculus Alpl gene Proteins 0.000 description 4
• 201000004404 Neurofibroma Diseases 0.000 description 4
• 101150083321 Nf1 gene Proteins 0.000 description 4
• 208000001697 Odontohypophosphatasia Diseases 0.000 description 4
• 101710118538 Protease Proteins 0.000 description 4
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
• 208000005065 achondrogenesis Diseases 0.000 description 4
• 208000004064 acoustic neuroma Diseases 0.000 description 4
• 201000007047 acrodysostosis Diseases 0.000 description 4
• HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 4
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 201000007845 atelosteogenesis Diseases 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 208000001020 chondrodysplasia punctata Diseases 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 239000003479 dental cement Substances 0.000 description 4
• 201000007394 diastrophic dysplasia Diseases 0.000 description 4
• 208000003350 fibrochondrogenesis Diseases 0.000 description 4
• 210000002683 foot Anatomy 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 150000002333 glycines Chemical class 0.000 description 4
• 230000013595 glycosylation Effects 0.000 description 4
• 238000006206 glycosylation reaction Methods 0.000 description 4
• 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 4
• 230000000004 hemodynamic effect Effects 0.000 description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 229910052500 inorganic mineral Inorganic materials 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 210000001872 metatarsal bone Anatomy 0.000 description 4
• 229930182817 methionine Natural products 0.000 description 4
• 239000011707 mineral Substances 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• 208000005368 osteomalacia Diseases 0.000 description 4
• 208000027612 peripheral dysostosis Diseases 0.000 description 4
• 108010031345 placental alkaline phosphatase Proteins 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 230000004481 post-translational protein modification Effects 0.000 description 4
• 238000002864 sequence alignment Methods 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 201000003504 spondyloepiphyseal dysplasia congenita Diseases 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
• IQQWMJSNEUUJAY-UHFFFAOYSA-D trialuminum;sodium;dihydrogen phosphate;hydrogen phosphate;tetrahydrate Chemical compound O.O.O.O.[Na+].[Al+3].[Al+3].[Al+3].OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP([O-])([O-])=O.OP([O-])([O-])=O IQQWMJSNEUUJAY-UHFFFAOYSA-D 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 3
• 102100025677 Alkaline phosphatase, germ cell type Human genes 0.000 description 3
• 208000025490 Apert syndrome Diseases 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 201000001200 Crouzon syndrome-acanthosis nigricans syndrome Diseases 0.000 description 3
• 206010011878 Deafness Diseases 0.000 description 3
• 208000000088 Enchondromatosis Diseases 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 206010053759 Growth retardation Diseases 0.000 description 3
• 101000574440 Homo sapiens Alkaline phosphatase, germ cell type Proteins 0.000 description 3
• 102000004877 Insulin Human genes 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 3
• 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 3
• 229940124647 MEK inhibitor Drugs 0.000 description 3
• 208000007326 Muenke Syndrome Diseases 0.000 description 3
• 208000003452 Multiple Hereditary Exostoses Diseases 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 208000004286 Osteochondrodysplasias Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 229920000805 Polyaspartic acid Polymers 0.000 description 3
• 108010020346 Polyglutamic Acid Proteins 0.000 description 3
• 208000002607 Pseudarthrosis Diseases 0.000 description 3
• 208000001647 Renal Insufficiency Diseases 0.000 description 3
• 206010042778 Syndactyly Diseases 0.000 description 3
• DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 101150000740 ana gene Proteins 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 210000002805 bone matrix Anatomy 0.000 description 3
• 201000006715 brachydactyly Diseases 0.000 description 3
• 201000005973 campomelic dysplasia Diseases 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 210000000038 chest Anatomy 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 210000004489 deciduous teeth Anatomy 0.000 description 3
• 238000010586 diagram Methods 0.000 description 3
• OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical group O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 description 3
• 238000003182 dose-response assay Methods 0.000 description 3
• 230000008030 elimination Effects 0.000 description 3
• 238000003379 elimination reaction Methods 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 201000010103 fibrous dysplasia Diseases 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000001415 gene therapy Methods 0.000 description 3
• 231100000001 growth retardation Toxicity 0.000 description 3
• 210000004247 hand Anatomy 0.000 description 3
• 208000016354 hearing loss disease Diseases 0.000 description 3
• 208000003906 hydrocephalus Diseases 0.000 description 3
• 239000000017 hydrogel Substances 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 229940125396 insulin Drugs 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 230000000366 juvenile effect Effects 0.000 description 3
• 201000006370 kidney failure Diseases 0.000 description 3
• 210000002414 leg Anatomy 0.000 description 3
• OTXBNHIUIHNGAO-UHFFFAOYSA-N leucyl-lysine Chemical compound CC(C)CC(N)C(=O)NC(C(O)=O)CCCCN OTXBNHIUIHNGAO-UHFFFAOYSA-N 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 208000011426 mesomelic dysplasia Diseases 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 208000002865 osteopetrosis Diseases 0.000 description 3
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 230000036470 plasma concentration Effects 0.000 description 3
• 239000004014 plasticizer Substances 0.000 description 3
• 108010064470 polyaspartate Proteins 0.000 description 3
• 229920002643 polyglutamic acid Polymers 0.000 description 3
• 108091033319 polynucleotide Proteins 0.000 description 3
• 239000002157 polynucleotide Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 238000011287 therapeutic dose Methods 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 210000004291 uterus Anatomy 0.000 description 3
• 230000004584 weight gain Effects 0.000 description 3
• 235000019786 weight gain Nutrition 0.000 description 3
• ZRMMVODKVLXCBB-UHFFFAOYSA-N 1-n-cyclohexyl-4-n-phenylbenzene-1,4-diamine Chemical compound C1CCCCC1NC(C=C1)=CC=C1NC1=CC=CC=C1 ZRMMVODKVLXCBB-UHFFFAOYSA-N 0.000 description 2
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• 208000009304 Acute Kidney Injury Diseases 0.000 description 2
• 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
• 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 2
• 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
• 208000000412 Avitaminosis Diseases 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
• 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 208000009447 Cardiac Edema Diseases 0.000 description 2
• 206010007556 Cardiac failure acute Diseases 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 206010067380 Costello Syndrome Diseases 0.000 description 2
• 101710095468 Cyclase Proteins 0.000 description 2
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
• 208000018035 Dental disease Diseases 0.000 description 2
• 206010012559 Developmental delay Diseases 0.000 description 2
• NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
• 208000031213 Epidermal nevus syndrome Diseases 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 206010015995 Eyelid ptosis Diseases 0.000 description 2
• 208000016264 Femoral agenesis/hypoplasia Diseases 0.000 description 2
• 206010017076 Fracture Diseases 0.000 description 2
• 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
• 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
• 208000006334 Gingival Fibromatosis Diseases 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 229930186217 Glycolipid Natural products 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 208000030839 Hereditary gingival fibromatosis Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000961040 Homo sapiens Atrial natriuretic peptide receptor 2 Proteins 0.000 description 2
• 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 206010021135 Hypovitaminosis Diseases 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• 208000010809 Ito hypomelanosis Diseases 0.000 description 2
• 208000009289 Jackson-Weiss syndrome Diseases 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
• 208000005101 LEOPARD Syndrome Diseases 0.000 description 2
• 208000006286 Legius syndrome Diseases 0.000 description 2
• 208000006824 Lichtenstein syndrome Diseases 0.000 description 2
• 208000035752 Live birth Diseases 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 2
• 206010062901 Multiple lentigines syndrome Diseases 0.000 description 2
• 208000010428 Muscle Weakness Diseases 0.000 description 2
• 206010028372 Muscular weakness Diseases 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 208000032158 Nievergelt type mesomelic dwarfism Diseases 0.000 description 2
• 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 208000005141 Otitis Diseases 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• 201000004014 Pfeiffer syndrome Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 208000033626 Renal failure acute Diseases 0.000 description 2
• 208000005568 Robinow syndrome Diseases 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 208000009163 Sebaceous of Jadassohn Nevus Diseases 0.000 description 2
• YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 2
• 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 208000008312 Tooth Loss Diseases 0.000 description 2
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000014070 Vestibular schwannoma Diseases 0.000 description 2
• 229930003268 Vitamin C Natural products 0.000 description 2
• 208000026724 Waardenburg syndrome Diseases 0.000 description 2
• 208000021017 Weight Gain Diseases 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 201000011040 acute kidney failure Diseases 0.000 description 2
• 208000012998 acute renal failure Diseases 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000003125 aqueous solvent Substances 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 210000004507 artificial chromosome Anatomy 0.000 description 2
• 210000000270 basal cell Anatomy 0.000 description 2
• 230000002146 bilateral effect Effects 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 230000008468 bone growth Effects 0.000 description 2
• 244000309464 bull Species 0.000 description 2
• 208000014729 capillary malformation Diseases 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 208000002458 carcinoid tumor Diseases 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 230000035487 diastolic blood pressure Effects 0.000 description 2
• FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 208000019258 ear infection Diseases 0.000 description 2
• 239000002702 enteric coating Substances 0.000 description 2
• 238000009505 enteric coating Methods 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 208000009618 familial spinal neurofibromatosis Diseases 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
• 239000001087 glyceryl triacetate Substances 0.000 description 2
• 235000013773 glyceryl triacetate Nutrition 0.000 description 2
• 210000004349 growth plate Anatomy 0.000 description 2
• 231100000888 hearing loss Toxicity 0.000 description 2
• 230000010370 hearing loss Effects 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 210000002758 humerus Anatomy 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
• 208000011111 hypophosphatemic rickets Diseases 0.000 description 2
• 230000001077 hypotensive effect Effects 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 206010024217 lentigo Diseases 0.000 description 2
• 208000020038 linear nevus sebaceous syndrome Diseases 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 description 2
• 230000002071 myeloproliferative effect Effects 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 230000001452 natriuretic effect Effects 0.000 description 2
• 239000006225 natural substrate Substances 0.000 description 2
• 208000024550 neurocutaneous melanocytosis Diseases 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 206010031281 osteopoikilosis Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 238000002732 pharmacokinetic assay Methods 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 208000028591 pheochromocytoma Diseases 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 208000031223 plasma cell leukemia Diseases 0.000 description 2
• 235000017924 poor diet Nutrition 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 201000003004 ptosis Diseases 0.000 description 2
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
• 210000002320 radius Anatomy 0.000 description 2
• 108010023714 recombinant human bone morphogenetic protein-2 Proteins 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 208000037803 restenosis Diseases 0.000 description 2
• 206010039722 scoliosis Diseases 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 208000005198 spinal stenosis Diseases 0.000 description 2
• 201000010809 spondyloepimetaphyseal dysplasia Diseases 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000035488 systolic blood pressure Effects 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 229960002622 triacetin Drugs 0.000 description 2
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
• 208000009999 tuberous sclerosis Diseases 0.000 description 2
• 229910052721 tungsten Inorganic materials 0.000 description 2
• 241000990167 unclassified Simian adenoviruses Species 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 235000019154 vitamin C Nutrition 0.000 description 2
• 239000011718 vitamin C Substances 0.000 description 2
• 208000030401 vitamin deficiency disease Diseases 0.000 description 2
• 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
• 206010000349 Acanthosis Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000021969 Acromelia Diseases 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 101150014183 Alpl gene Proteins 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 208000008822 Ankylosis Diseases 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 102100024522 Bladder cancer-associated protein Human genes 0.000 description 1
• 101150110835 Blcap gene Proteins 0.000 description 1
• 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 206010048409 Brain malformation Diseases 0.000 description 1
• GOJCZVPJCKEBQV-UHFFFAOYSA-N Butyl phthalyl butylglycolate Chemical compound CCCCOC(=O)COC(=O)C1=CC=CC=C1C(=O)OCCCC GOJCZVPJCKEBQV-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 206010007747 Cataract congenital Diseases 0.000 description 1
• ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
• 208000003417 Central Sleep Apnea Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009269 Cleft palate Diseases 0.000 description 1
• 201000000304 Cleidocranial dysplasia Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 206010066946 Craniofacial dysostosis Diseases 0.000 description 1
• 108010051219 Cre recombinase Proteins 0.000 description 1
• 201000006526 Crouzon syndrome Diseases 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
• 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 208000013805 Dyggve-Melchior-Clausen disease Diseases 0.000 description 1
• 101150029662 E1 gene Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 229920003134 Eudragit® polymer Polymers 0.000 description 1
• 108091008794 FGF receptors Proteins 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 208000001951 Fetal Death Diseases 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
• 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
• 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
• 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
• 208000008961 Fibrous Dysplasia of Bone Diseases 0.000 description 1
• 206010055690 Foetal death Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 108010078321 Guanylate Cyclase Proteins 0.000 description 1
• 102000014469 Guanylate cyclase Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000749809 Homo sapiens 2',3'-cyclic-nucleotide 3'-phosphodiesterase Proteins 0.000 description 1
• 101500027325 Homo sapiens Atrial natriuretic peptide Proteins 0.000 description 1
• 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
• 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 1
• 101000796277 Homo sapiens C-type natriuretic peptide Proteins 0.000 description 1
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
• 101500027331 Homo sapiens Urodilatin Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010021639 Incontinence Diseases 0.000 description 1
• 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
• 102100021496 Insulin-degrading enzyme Human genes 0.000 description 1
• 108090000828 Insulysin Proteins 0.000 description 1
• 206010023198 Joint ankylosis Diseases 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical class OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 101710128836 Large T antigen Proteins 0.000 description 1
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
• 208000001826 Marfan syndrome Diseases 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 208000013669 Mesomelia Diseases 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 208000019724 Narrow chest Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• ARLZGEXVMUDUQZ-UHFFFAOYSA-N O.O.[Ca] Chemical compound O.O.[Ca] ARLZGEXVMUDUQZ-UHFFFAOYSA-N 0.000 description 1
• 101100493740 Oryza sativa subsp. japonica BC10 gene Proteins 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 208000012641 Pigmentation disease Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 206010036172 Porencephaly Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
• 208000033787 Rare developmental defect during embryogenesis Diseases 0.000 description 1
• 208000035977 Rare disease Diseases 0.000 description 1
• 208000012635 Rhizomelia Diseases 0.000 description 1
• 208000027790 Rib fracture Diseases 0.000 description 1
• 201000001718 Roberts syndrome Diseases 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000031709 Skin Manifestations Diseases 0.000 description 1
• 206010062348 Skull malformation Diseases 0.000 description 1
• 208000014151 Stomatognathic disease Diseases 0.000 description 1
• 208000013201 Stress fracture Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 108010076818 TEV protease Proteins 0.000 description 1
• 206010044443 Transposition of the great vessels Diseases 0.000 description 1
• 241000219793 Trifolium Species 0.000 description 1
• 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• 241000700647 Variola virus Species 0.000 description 1
• PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000000370 acceptor Substances 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 208000001884 acromesomelic dysplasia Diseases 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 208000008784 apnea Diseases 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 210000002072 atrial myocyte Anatomy 0.000 description 1
• 206010003664 atrial septal defect Diseases 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 238000002869 basic local alignment search tool Methods 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 238000006065 biodegradation reaction Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 238000007470 bone biopsy Methods 0.000 description 1
• 210000002449 bone cell Anatomy 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• 229910052793 cadmium Inorganic materials 0.000 description 1
• BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
• 230000002308 calcification Effects 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 208000012056 cerebral malformation Diseases 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000013267 controlled drug release Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 210000000877 corpus callosum Anatomy 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 238000005115 demineralization Methods 0.000 description 1
• 230000002328 demineralizing effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 208000022734 developmental defect during embryogenesis Diseases 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• PCYQQSKDZQTOQG-NXEZZACHSA-N dibutyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCCCOC(=O)[C@H](O)[C@@H](O)C(=O)OCCCC PCYQQSKDZQTOQG-NXEZZACHSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
• 229960001826 dimethylphthalate Drugs 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000005221 enamel hypoplasia Effects 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 231100000479 fetal death Toxicity 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 210000003811 finger Anatomy 0.000 description 1
• 235000021323 fish oil Nutrition 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 230000030414 genetic transfer Effects 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 230000036449 good health Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 210000002837 heart atrium Anatomy 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 102000047974 human CNP Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 201000009075 hydranencephaly Diseases 0.000 description 1
• 150000001261 hydroxy acids Chemical class 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 201000003723 learning disability Diseases 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229910001425 magnesium ion Inorganic materials 0.000 description 1
• 208000035853 malformation syndrome Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 238000005621 mannosylation reaction Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 238000010603 microCT Methods 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000003595 mist Substances 0.000 description 1
• 238000009126 molecular therapy Methods 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• JSOQIZDOEIKRLY-UHFFFAOYSA-N n-propylnitrous amide Chemical compound CCCNN=O JSOQIZDOEIKRLY-UHFFFAOYSA-N 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 230000006548 oncogenic transformation Effects 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000002379 periodontal ligament Anatomy 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 235000003784 poor nutrition Nutrition 0.000 description 1
• 235000015277 pork Nutrition 0.000 description 1
• 230000007542 postnatal development Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
• 229960001327 pyridoxal phosphate Drugs 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000009256 replacement therapy Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 235000021309 simple sugar Nutrition 0.000 description 1
• 231100001055 skeletal defect Toxicity 0.000 description 1
• 208000025869 skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 229940031626 subunit vaccine Drugs 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000019635 sulfation Effects 0.000 description 1
• 238000005670 sulfation reaction Methods 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 210000003813 thumb Anatomy 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 208000014903 transposition of the great arteries Diseases 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• YZWRNSARCRTXDS-UHFFFAOYSA-N tripropionin Chemical compound CCC(=O)OCC(OC(=O)CC)COC(=O)CC YZWRNSARCRTXDS-UHFFFAOYSA-N 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000005243 upper chamber Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 230000006442 vascular tone Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 235000019158 vitamin B6 Nutrition 0.000 description 1
• 239000011726 vitamin B6 Substances 0.000 description 1
• 229940011671 vitamin b6 Drugs 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000000707 wrist Anatomy 0.000 description 1